Psycho-oncology: Review and update
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The field of psycho-oncology is moving forward rapidly, especially for a relatively new field. Cancer patients and survivors are willing to discuss their needs and interests relating to diagnosis and treatment. There are guidelines and algorithms for determining levels of distress in cancer patients in both inpatient and outpatient settings. The pharmacologic treatment of distress, particularly depression, has vastly improved. Randomized controlled trials are becoming available for patients in order to determine the efficacy of psychotropic drugs. Numerous interventions are available to help cancer patients move forward with their lives. Some of these interventions began in the 1980s and have progressed to the use of complementary and alternative medicine techniques as coping strategies for cancer. With the rapid expansion of the Internet, cancer survivors’ thirst for information also has grown. Many resources are available to help guide cancer patients through the maze of the diagnosis and treatment of cancer.
- American Cancer Society: Cancer Facts and Figures. New York: American Cancer Society; 2006.
- Derogatis LR, Morrow GR, Fetting J, et al.: The prevalence of psychiatric disorders among cancer patients. JAMA 1983, 249:751–757. CrossRef
- Stefanek ME, Derogatis LP, Shaw A: Psychological distress among oncology outpatients: prevalence and severity as measured with the Belief Symptom Inventory. Psychosomatics 1987, 28:530–532.
- Roth AJ, Kornblith AB, Batel-Copel L, et al.: Rapid screening for psychologic distress in men with prostate carcinoma; a pilot study. Cancer 1998, 82:1904–1908. CrossRef
- Holland JC: Distress management. In NCCN Clinical Practice Guidelines in Oncology [CD-ROM], version 2, Jenkintown, PA: National Comprehensive Cancer Network; 2005. These guidelines are based on algorithms for determining which patients suffer distress, what problems are related to those distress levels, and the course of action that should be taken. This is the first sophisticated method for identifying the needs of cancer patients in distress and directions for the resolution of symptoms.
- Jacobsen PB, Donovan KA, Trask PC, et al.: Screening for psychologic distress in ambulatory cancer patients. Cancer 2005, 103:1494–1502. CrossRef
- Hoffman BM, Zevon MA, D’Arrigo MC, Cecchini TB: Screening for distress in cancer patients: the NCCN rapidscreening measure. Psychooncology 2004, 13:792–799. CrossRef
- Söllner W, Maislinger S, Konig A, et al.: Providing psychosocial support for breast cancer patients based on screening for distress within a consultation-liaison service. Psychooncology 2004, 13:893–897. CrossRef
- Shimizu K, Akechi T, Okamura M, et al.: Usefulness of the nurse-assisted screening and psychiatric referral program. Cancer 2005, 103:1949–1956. CrossRef
- Lee SJ, Loberiza FR, Antin JH, et al.: Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant 2005, 35:77–83. CrossRef
- Physicians’ Desk Reference, edn 60. Montvale, NJ: Thomson Healthcare; 2006.
- Duffy LS, Greenberg DB, Younger J, et al.: Iatrogenic acute estrogen deficiency and psychiatric syndromes in breast cancer patients. Psychosomatics 1999, 40:304–308.
- Day R, Ganz PA, Costantino JP, et al.: Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999, 17:2659–2669.
- Fallowfield L, Fleissig A, Edwards R, et al.: Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 2001, 19:1885–1892.
- Costa D, Mogos I, Toma T: Efficacy and safety of mianserin in the treatment of depression of women with cancer. Acta Psychiatr Scand Suppl 1985, 320:85–92.
- Razavi D, Allilaire JF, Smith M, et al.: The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 1996, 94:205–210.
- Fisch MJ, Loehrer PJ, Kristeller J, et al.: Fluoxetine versus placebo in advanced cancer outpatients: a doubleblinded trial of the Hoosier Oncology Group. J Clin Oncol 2003, 21:1937–1943. CrossRef
- Morrow GR, Hickok JT, Roscoe JA, et al.: Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003, 21:4635–4641. CrossRef
- Roscoe JA, Morrow GR, Hickok JT, et al.: Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005, 89:243–249. CrossRef
- Musselman DL, Somerset WI, Guo Y, et al.: A doubleblind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry 2006, 67:288–296. CrossRef
- Holland JC, Roman SJ, Heiligenstein JH, et al.: A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 1998, 7:291–300. CrossRef
- Pezzella G, Moslinger-Gehmayr R, Contu A: Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 2001, 70:1–10. CrossRef
- Theobald DE, Kirsh KL, Holtsclaw E, et al.: An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002, 23:442–447. CrossRef
- Van Gool AR, Bannink M, Stronks DL, Vos MS: Re: Mirtazapine in cancer patients. J Pain Symptom Manag 2003, 25:7–8. CrossRef
- Grassi L, Biancosino B, Marmail L, Righi R: Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. J Clin Psychiatry 2004, 65:515–520. CrossRef
- Pae CU, Kim YJ, Won WY, et al.: Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. Hum Psychopharmacol 2004, 19:25–29. CrossRef
- Gothelf D, Rubinstein M, Shemesh E, et al.: Pilot study: fluvoxamine treatment for depression and anxiety disorders in children and adolescents with cancer. J Am Acad Child Adolesc Psychiatry 2005, 44:1258–1262. CrossRef
- Bruera E, Driver L, Barnes EA, et al.: Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003, 21:4439–4443. CrossRef
- Homsi J, Nelson KA, Sarhill N, et al.: A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 2001, 18:403–407. CrossRef
- Musselman DL, Lawson DH, Gumnick JF, et al.: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961–966. CrossRef
- Loprinzi CL, Kugler JW, Sloan JA, et al.: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000, 356:2059–2063. This was one of the first studies with a large sample size that used a randomized controlled trial with three different doses of venlafaxine. CrossRef
- Loprinzi CL, Sloan JA, Perez EA, et al.: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002, 20:1578–1583. CrossRef
- Stearns V, Slack R, Greep N, et al.: Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005, 23:6919–6930. CrossRef
- Pandya KJ, Morrow GR, Roscoe JA, et al.: Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005, 366:818–824. CrossRef
- Cotterchio M, Kreiger N, Darlington G, et al.: Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000, 151:951–957.
- Sharpe CR, Collet J-P, Belzille E, et al.: The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer 2002, 86:92–97. CrossRef
- Kurdyak PA, Gnam WH, Streiner DL: Antidepressants and the risk of breast cancer [review]. Can J Psychiatry 2002, 47:966–970.
- Bahl S, Cotterchio M, Kreiger N: Use of antidepressant medications and the possible association with breast cancer risk. A review. Psychother Psychosom 2003, 72:185–194. CrossRef
- Lawlor DA, Juni P, Ebrahim S, et al.: Systematic review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol 2003, 56:155–163. CrossRef
- Sternbach H: Are antidepressants carcinogenic? A review of preclinical and clinical studies. Clin Psychiatry 2003, 64:1153–1162. This is a complete review of both preclinical and clinical studies of the topic. The clinical studies are summarized in a helpful table. CrossRef
- Lovejoy NC, Tabor D, Matteis M, Lillis P: Cancer-related depression: Part I—neurologic alterations and cognitive-behavioral therapy [review]. Oncol Nurs Forum 2000, 27:667–678.
- Potash M, Breitbart W: Affective disorders in advanced cancer [review]. Hematol Oncol Clin North Am 2002, 16:671–700. This is likely to be the best broad article to read first about mood disorders in cancer patients. It covers the entire topic: prevalence, diagnosis, risk factors, and treatment. After reading this, readers can look at more specialized articles as needed. CrossRef
- Bronheim HE, Fulop G, Kunkel EJ, et al.: The Academy of Psychosomatic Medicine practice guidelines for psychiatric consultation in the general medical setting. Psychosomatics 1998, 39:S8-S30.
- Beck AT, Guth D, Steer RA, Ball R: Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther 1997, 35:785–791. CrossRef
- Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361–370.
- Noyes R, Kathol RG, Debelius-Enemark P, et al.: Distress associated with cancer as measured by the illness distress scale. Psychosomatics 1990, 31:321–330.
- Thoits PA: Life stress, social support, and psychological vulnerability: epidemiological considerations [review]. J Community Psychol 1982, 10:341–362. CrossRef
- Bruce ML, Hoff RA: Social and physical health risk factors for first-onset major depressive disorder in a community sample. Soc Psychiatry Psychiatr Epidemiol 1994, 29:165–171.
- Moorey S, Greer S: Psychological Therapy for Patients with Cancer: A New Approach. Oxford: Heinemann Medical Books; 1989.
- Moorey S, Greer S, Bliss J, Law M: A comparison of adjuvant psychological therapy and supportive counseling in patients with cancer. Psychooncology 1998, 7:218–228. This was the first study to demonstrate that adjuvant psychological therapy is superior to supportive counseling in cancer patients. This pioneering work led the way for others to investigate psychological therapies for cancer patients. CrossRef
- Antoni MH, Lehman JM, Kilbourn KM, et al.: Cognitivebehavioral stress management intervention decreases the prevalence of depression and enhances benefit finding among women under treatment for early-stage breast cancer. Health Psychol 2001, 20:20–32. This article reported that the intervention group using cognitivebehavioral stress management improved significantly on measures of depressive symptoms, emotional disturbance, optimism, and benefit finding. It emphasized the importance of collecting information on positive and negative experiences when looking at people dealing with adversity. CrossRef
- Given C, Given B, Rahbar M, et al.: Effect of cognitive behavioral intervention on reducing symptom severity during chemotherapy. J Clin Oncol 2004, 22:507–516. This study was one of the first to report that patients in the experimental intervention group had significantly lower levels of symptom severity during chemotherapy than the control group. CrossRef
- Goodwin PJ, Leszcz M, Ennis M, et al.: The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001, 345:1719–1726. This was the largest trial of investigating survival rates in women with breast cancer in relationship to their participation in a psychosocial support group. CrossRef
- Petersen RW, Quinlivan JA: Preventing anxiety and depression in gynaecological cancer: a randomised controlled trial. BJOG 2002, 109:386–394. CrossRef
- Sloman R: Relaxation and imagery for anxiety and depression control in community patients with advanced cancer. Cancer Nurs 2002, 25:432–435. CrossRef
- Stephenson NL, Weinrich SP, Tavakoli AS: The effects of foot refiexology on anxiety and pain in patients with breast and lung cancer. Oncol Nurs Forum 2000, 27:67–72.
- Levine EG, Eckhardt J, Targ E: Change in post-traumatic stress symptoms following psychosocial treatment in breast cancer. Psychooncology 2005, 14:618–635. CrossRef
- Psycho-oncology: Review and update
Current Psychiatry Reports
Volume 8, Issue 3 , pp 246-252
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links